Related Experiment Video
Updated: Sep 18, 2025
Exploring m6A and m5C Epitranscriptomes upon Viral Infection: an Example with HIV
Published on: March 5, 2022
Unraveling m6A RNA methylation: From epitranscriptomics to therapeutic frontiers in renal cell carcinoma
Tingfei Xie1, Jiahui Chen1, Xiaolu Sui1
1Department of Nephrology, The People's Hospital of Baoan Shenzhen, The Second Affiliated Hospital of Shenzhen University, Shenzhen Hospital of Guangdong Provincial People's Hospital, The Affiliated Baoan Hospital of Southern Medical University, Shenzhen Baoan Clinical Medical School of Guangdong Medical University, The 8th people's Hospital of Shenzhen, Baoan Clinical Research Center for Kidney Disease, Guangdong 518000, PR China.
Abstract:
N6-methyladenosine (m6A) RNA methylation has emerged as a crucial regulatory mechanism in cancer biology, influencing processes such as RNA splicing, stability, translation, and degradation. Renal cell carcinoma (RCC), often referred to as a silent cancer, is one of the most common malignancies of the urinary tract and is associated with poor prognosis and inadequate treatment options. m6A modifications play a pivotal role in RCC tumorigenesis, metastasis, progression, immune response modulation, and therapy resistance. This review provides a comprehensive overview of the current understanding of m6A in RCC, discussing key m6A regulators and their roles as potential biomarkers and therapeutic targets. Furthermore, we explore advanced technologies like single-cell omics and machine learning in elucidating the role of m6A in RCC, facilitating the search for effective therapeutic targets. Future directions focus on translating these findings into clinical applications, with a view toward personalized medicine and combination therapies.
Insights
N6-methyladenosine (m6A) RNA methylation is key in renal cell carcinoma (RCC) development and progression. Understanding m6A regulators offers new therapeutic targets for this challenging cancer.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- N6-methyladenosine (m6A) RNA methylation is a critical epigenetic mechanism influencing gene expression.
- Renal cell carcinoma (RCC) is a prevalent urinary tract malignancy with poor prognosis and limited treatment options.
- m6A modifications are implicated in RCC tumorigenesis, metastasis, immune evasion, and therapeutic resistance.
Purpose of the Study:
- To provide a comprehensive review of the role of m6A RNA methylation in renal cell carcinoma.
- To identify key m6A regulators as potential biomarkers and therapeutic targets in RCC.
- To explore advanced technologies for elucidating m6A functions in RCC and guiding treatment strategies.
Main Methods:
- Literature review of m6A modifications in RCC.
- Analysis of m6A regulators' roles in RCC pathogenesis and progression.
- Exploration of single-cell omics and machine learning applications in RCC research.
Main Results:
- m6A RNA methylation significantly impacts multiple facets of RCC, including tumor initiation, spread, and immune response.
- Specific m6A regulators demonstrate potential as prognostic biomarkers and therapeutic targets for RCC.
- Advanced technologies offer novel insights into m6A-driven mechanisms in RCC.
Conclusions:
- m6A RNA methylation is a crucial player in renal cell carcinoma biology.
- Targeting m6A regulators presents a promising avenue for novel RCC therapies.
- Future research should focus on clinical translation for personalized RCC treatment approaches.
Related Concept Videos
01:53RNA Stability
01:22MicroRNAs
02:23RNA Editing